# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Fannie Lou Hamer (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML031-SYN-TD
- Date: 1967-07-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Batiste-Hill, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-month review: A1c, urine albumin, kidney function, mood, social needs, and the metformin dose. **S**

## History of present illness

Mrs. Hamer returns two months after her last review, brought by the health center's van as booked. Her home readings averaged 131/82 at the four-week phone check and 127/79 since, so no dose change was needed. She has had no low blood sugar, dizziness, cough or genital itching. She has finished the diabetes classes. The energy assistance was approved, and with SNAP and the produce program the food lasts through the month. She walks most days, though her legs ache. Her mood is steady. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 127/79 |
| Diabetes classes | Completed |
| Benefits | SNAP and energy assistance in place |
| Mood | PHQ-9 3 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No dizziness; weight down 2 kg |
| Cardiovascular | Negative | No ankle swelling |
| Genitourinary | Negative | No burning or genital itching |
| Musculoskeletal | Positive | Leg aching after walking |
| Psychiatric | Negative | Mood steady |

5 systems reviewed. **S**

## Current medications

- Metformin extended-release 500 mg oral tablet, three tablets with the evening meal **S**
- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Amlodipine 5 mg and benazepril 20 mg combined oral capsule, one capsule daily **S**
- Dapagliflozin 10 mg oral tablet, one tablet daily; stop on days of vomiting, diarrhea or not eating, and before surgery **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.9 °C; oxygen saturation 98% on room air; weight 90.9 kg; BMI 34.2 kg/m². All vital signs are synthetic.

Hemoglobin A1c: 7.3% (high); Urine albumin-to-creatinine ratio: 52 mg/g (high); Potassium: 4.6 mmol/L; Creatinine: 1.02 mg/dL; eGFR (CKD-EPI 1962): 67 mL/min/1.73 m² (low); PHQ-9: 3; AHC-HRSN screen: core needs positive (0 to 5): 1. All results are synthetic.

## Change since baseline

- Hemoglobin A1c: 8.6% (high) at baseline, 7.3% (high) at this visit **S**
- Urine albumin-to-creatinine ratio: 88 mg/g (high) at baseline, 52 mg/g (high) at this visit **S**
- Potassium: 4.3 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Creatinine: 0.96 mg/dL at baseline, 1.02 mg/dL at this visit **S**
- eGFR (CKD-EPI 1962): 73 mL/min/1.73 m² (low) at baseline, 67 mL/min/1.73 m² (low) at this visit **S**
- PHQ-9: 4 at baseline, 3 at this visit **S**
- AHC-HRSN screen: core needs positive (0 to 5): 3 at baseline, 1 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| Consent and chaperone | Blood draw, urine sample and examination explained and agreed; female nurse present |
| General | Well; blood pressure 128/78, pulse 76; weight 90.9 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Feet | Inspected with her agreement: callus smaller after trimming; no ulcers |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Type 2 diabetes** (E11.65). A1c 7.3%, from 8.6%; no low blood sugar. Just above goal. **S**
   - Increase metformin extended-release to three tablets (1,500 mg) with the evening meal.
   - A1c again in three months.
2. **Chronic kidney disease G2 A2** (N18.2). Urine albumin-to-creatinine ratio 52 mg/g, down from 96; potassium 4.6 mmol/L; creatinine 1.02 mg/dL, eGFR 67: stable. **S**
   - Continue benazepril and dapagliflozin.
   - Urine albumin again in three months.
3. **Hypertension with chronic kidney disease** (I12.9). At goal at home and in the clinic. **S**
   - Continue amlodipine-benazepril; home readings twice a week.
4. **Transportation insecurity** (Z59.82). Van rides booked for every visit since the missed check; other trips still uncertain. AHC screen now positive for transportation only. **S**
   - Keep rides booked at each visit; phone visits when travel is not possible.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Consent and chaperone for every examination, test and procedure | Every visit | Completed today | Each step explained and agreed |
| Examination | Clinic blood pressure (seated, two readings, large cuff) | Every visit | Completed today | 128/78 |
| Self-management | Home blood pressure readings | Seven days to confirm the diagnosis; then twice a week, and daily for a week after any change | Completed today | Average 127/79 |
| Examination | Weight and BMI | Every visit | Completed today | 90.9 kg |
| Laboratory | Hemoglobin A1c | Every 3 months until at goal, then every 6 months | Completed today | 7.3%, from 8.6% |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; 3 to 6 months after a treatment change; then every 6 months while moderately increased | Completed today | 52 mg/g, from 96 |
| Laboratory | Potassium, creatinine and eGFR | One to two weeks after starting an ACE inhibitor, then every 6 months (more often with changes) | Completed today | Potassium 4.6 mmol/L; creatinine 1.02 mg/dL, eGFR 67 |
| Examination | Foot inspection, and comprehensive foot examination | Inspection every visit; comprehensive examination yearly | Completed today | Inspection: callus smaller; no ulcers |
| Medication safety | Medicine safety: low blood sugar, sick-day rules, genital infections, cough, swelling, adherence and cost | Every visit | Completed today | No low blood sugar, dizziness, cough or genital itching; metformin increased |
| Self-management | Diabetes self-management education and support | At diagnosis, then yearly and when needs change | Completed today | Classes completed |
| Survey | Depression screen (PHQ-9) | At intake, then every 6 to 12 months | Completed today | PHQ-9 3, asked privately |
| Survey | Social needs screen (AHC-HRSN) and resources | At intake, then every few months while needs are open | Completed today | One core need positive (transportation on some days); food and utility needs met |

## Goal progress

- Every examination, test and procedure explained first and done only with her documented agreement, with a chaperone of her choosing, at every visit. In progress; target 1967-10-19. **S**
- Blood pressure below 130/80 mmHg in the clinic and at home within six months. In progress; target 1967-10-19. **S**
- A1c below 7% within six to nine months, without low blood sugar. In progress; target 1967-10-19. **S**
- Urine albumin-to-creatinine ratio lower by at least 30% within six months. In progress; target 1967-10-19. **S**
- Food and utility needs met through benefits, and a dependable way to reach every visit and laboratory test. In progress; target 1967-10-19. **S**
- LDL cholesterol below 70 mg/dL. In progress; target 1967-10-19. **S**

## Medication changes

- Stopped: Metformin extended-release 500 mg oral tablet, one tablet with the evening meal for one week, then two tablets with the evening meal **S**
- Started: Metformin extended-release 500 mg oral tablet, three tablets with the evening meal **S**

## Guideline basis

- Introduction and Methodology: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- CMID: Clinical Monitoring Intelligence Database, hypertension, diabetes type 2, hyperlipidemia, chronic kidney disease and depression monographs (2026), Aether Forge
- Trauma-Informed Care in Behavioral Health Services (Treatment Improvement Protocol 57) (2014), Substance Abuse and Mental Health Services Administration
- Code of Medical Ethics Opinion 2.1.1: Informed Consent (2026), American Medical Association
- The Accountable Health Communities Health-Related Social Needs Screening Tool (2017), Centers for Medicare & Medicaid Services
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Preventive visit in two months. Seven-month review in three months with the A1c, urine albumin, kidney function, the social needs screen and the autumn vaccines; rides booked. **S**
- Next scheduled visit 1967-09-14: periodic adult preventive visit. **S**
